Abstract
Tamoxifen significantly improves outcome for estrogen receptor-positive (ER+) breast cancer, but the 15-year recurrence rate remains 30%. The aim of this study was to identify gene profiles that accurately predicted the outcome of ER+ breast cancer patients who received adjuvant Tamoxifen mono-therapy.
| Original language | English |
|---|---|
| Journal | P L o S One |
| Volume | 8 |
| Issue number | 1 |
| Pages (from-to) | e54078 |
| ISSN | 1932-6203 |
| DOIs | |
| Publication status | Published - 2013 |
Keywords
- Aged
- Breast Neoplasms
- Cyclin-Dependent Kinase Inhibitor p21
- Female
- Humans
- Middle Aged
- Polymerase Chain Reaction
- Proto-Oncogene Proteins c-bcl-2
- Receptors, Estrogen
- Tamoxifen
Fingerprint
Dive into the research topics of 'Gene expression signatures that predict outcome of tamoxifen-treated estrogen receptor-positive, high-risk, primary breast cancer patients: a DBCG study'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS